Leukemia Research Foundation   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Northfield IL United States (1946)

Organization Overview

First Clinical Trial
1998
NCT00005823
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Leukemia Research Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hematologic Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Myelodysplastic-Myeloproliferative Diseases (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 22